Islet Sciences Announces Important Study Published in Diabetes Titled "Immune Therapy Reducing ß-Cel

Islet Sciences Announces Important Study Published in Diabetes Titled "Immune Therapy Reducing β-Cell Death in Type 1 Diabetes"

NEW YORK--(BUSINESS WIRE)-- Islet Sciences, Inc. (OTCBB:ISLT), (ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today an important study published in Diabetes by the American Diabetes Association titled Immune Therapy and β-Cell Death in Type 1 Diabetes.

"This study is another validator of our approach to tackling this worldwide disease," stated John Steel, Islet Sciences Chairman and Chief Executive Officer. "We continue to make solid important strides in executing our business strategy and this paper represents a clinical application of our licensed technology by leading scientists in the field of diabetes research."

Islet sciences appreciates and recognizes JDRF's support to Dr. Kevan Herold and Yale University in developing this technology.

Below is a copy of the abstract and a link to the article:

Immune Therapy and β-Cell Death in Type 1 Diabetes

Type 1 diabetes (T1D) results from immune-mediated destruction of insulin-producing β-cells. The killing of β-cells is not currently measurable; β-cell functional studies routinely used are affected by environmental factors such as glucose and cannot distinguish death from dysfunction. Moreover, it is not known whether immune therapies affect killing. We developed an assay to identify β-cell death by measuring relative levels of unmethylated INS DNA in serum and used it to measure β-cell death in a clinical trial of teplizumab. We studied 43 patients with recent-onset T1D, 13 nondiabetic subjects, and 37 patients with T1D treated with FcR nonbinding anti-CD3 monoclonal antibody (teplizumab) or placebo. Patients with recent-onset T1D had higher rates of β-cell death versus nondiabetic control subjects, but patients with long-standing T1D had lower levels. When patients with recent-onset T1D were treated with teplizumab, β-cell function was preserved (P < 0.05) and the rates of β-cell were reduced significantly (P < 0.05). We conclude that there are higher rates of β-cell death in patients with recent-onset T1D compared with nondiabetic subjects. Improvement in C-peptide responses with immune intervention is associated with decreased β-cell death.

Link to the article:

http://diabetes.diabetesjournals.org/content/early/2013/02/14/db12-1207.abstract

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes. The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti inflammatory compounds. For more information: www.isletsciences.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Islet Sciences Investor:
ProActive Capital Group
Jeff Ramson, 646-863-6893
jramson@proactivecapitalgroup.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS:

The article Islet Sciences Announces Important Study Published in Diabetes Titled "Immune Therapy Reducing β-Cell Death in Type 1 Diabetes" originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.